Hodgkin lymphomaA study looking at developing a quality of life questionnaire for people having adoptive cell therapy (iMATCH)
This study is looking at developing a quality of life questionnaire for people who are having an adoptive cell therapy.
Hodgkin lymphoma
Available
Available
A trial looking at MK-3475A for certain types of lymphoma (MK-3475A-F65)
This trial is looking at a new drug called MK-3475A for lymphoma that has come back or is getting worse despite treatment.
A trial looking at MK-4280A for Hodgkin lymphoma
This trial is looking at a new drug called MK-4280A for Hodgkin lymphoma.
A trial of treatment to prevent GvHD after a stem cell transplant (MoTD)
This trial is comparing standard treatment with 2 newer combinations of treatment to prevent GvHD.
A trial of pembrolizumab for Hodgkin lymphoma (KEYNOTE667)
This trial is looking at pembrolizumab after chemotherapy. It is open to children from 3 years old to young adults 25 years old with classical Hodgkin lymphoma.
A trial to improve treatment for children and young people with Hodgkin lymphoma (EuroNet PHL C2)
This trial is comparing different ways of treating Hodgkin lymphoma to help lower the risk of long term side effects.
A trial of avelumab for advanced Hodgkin lymphoma (AVENUE)
This trial is looking at having avelumab before standard chemotherapy for advanced Hodgkin lymphoma.
Hodgkin lymphoma survival by stage at diagnosis
When diagnosed at its earliest stage, more than 9 in 10 (97%) people with Hodgkin lymphoma will survive their disease for one year or more, compared with almost 9 in 10 (87%) people when the disease is diagnosed at the latest stage.
A trial of nivolumab for Hodgkin lymphoma (ANIMATE)
This trial is looking at nivolumab for people whose Hodgkin lymphoma has come back after initial chemotherapy or it didn’t work well enough.
Hodgkin lymphoma mortality trends over time
Since the early 1970s, Hodgkin lymphoma mortality rates have decreased by around three-quarters (74%) in the UK. Rates in females have decreased by more than seven-tenths (72%), and rates in males have decreased by around three-quarters (74%) (2017-2019).
Over the last decade, Hodgkin lymphoma mortality rates have remained stable in the UK. Rates in females have remained stable, and rates in males have remained stable (2017-2019).